The data, published in the journal Clinical Colorectal Cancer, supports the use of Cologuard every three years, in favorable comparison with using colonoscopy every 10 years.
“When a three-year Cologuard interval is modeled, Cologuard produces reductions in colon cancer incidence and related mortality similar to colonoscopy every 10 years. These significantly improved outcomes can be achieved at a reasonable cost for the millions of American who will not participate in colonoscopy screening, while providing less burden to patients, providers and health systems than annual screening,” said Kevin Conroy, chairman and CEO of Exact Sciences.
The modeling also found Cologuard to be a cost-effective option; following a positive test, three-year stool DNA testing costs $11,313 per quality adjusted life year compared with no screening.
More articles on gastroenterology:
EndoChoice expects $18.6M in Q4 revenue
6 GI physicians in the news – Jan. 8, 2016
GI physician leader: Dr. Howard Hack of Altru Health System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.